Bibliothek

X
feed icon rss

Ihre E-Mail wurde erfolgreich gesendet. Bitte prüfen Sie Ihren Maileingang.

Leider ist ein Fehler beim E-Mail-Versand aufgetreten. Bitte versuchen Sie es erneut.

Vorgang fortführen?

Exportieren
Filter
  • 1995-1999  (3)
  • 1990-1994  (1)
  • 1880-1889
  • Bladder cancer  (2)
  • Scopolamine  (2)
Datenquelle
Materialart
Erscheinungszeitraum
  • 1995-1999  (3)
  • 1990-1994  (1)
  • 1880-1889
Jahr
Schlagwörter
  • 1
    Digitale Medien
    Digitale Medien
    Scopolamine increases prehensile force during object manipulation by reducing palmar sweating and decreasing skin friction (1997)
    Springer
    Experimental brain research 114 (1997), S. 578-583 
    Details
    ISSN: 1432-1106
    Schlagwort(e): Key words Grasping ; Friction ; Sweat ; Scopolamine
    Quelle: Springer Online Journal Archives 1860-2000
    Thema: Medizin
    Notizen: Abstract  The aim of this study was to determine whether relatively long-term changes in skin friction induced by a pharmacological blockade of sweat excretion would alter the grip forces applied to objects of a variety of different surface textures and frictions. Five men and three women were asked to lift the vertically mounted armature of a linear motor between the thumb and index finger and to hold it against an opposing force for 2 s. A 1.0-kHz tone indicated to the subject that the manipulandum had been correctly positioned between the upper and lower position limits. The linear motor generated a 2.5-N force tangential to the skin surface simulating an object weighing approximately 250 g. Three different polyamide plastic surfaces (either smooth or etched with 1.0 mm high Braille beads evenly spaced at 2- or 3-mm intervals) contacted the fingers in these experiments. Subjects lifted and held in a precision grip one of the three surfaces for blocks of ten consecutive trials, but the order of presentation of the three different textures was varied to offset the effect of expectancy. On a second block of ten trials the subjects were requested to release the object slowly to measure the ratio of the grip force normal to the grasped surface to the tangential load force at the moment of slip. This ratio or its inverse provided the coefficient of friction or the slip ratio for a particular subject and surface condition. Twelve hours prior to a second recording session all subjects placed transdermal patches of 1.5 mg scopolamine behind each ear to reduce palmar sweating by blocking the muscarinic receptors of exocrine sweat glands. The subjects were re-tested following procedures that were identical to the first session. Scopolamine significantly reduced the friction of the skin on the smooth and 2-mm beaded surfaces, but the friction of the 3-mm beaded texture was unaffected. Scopolamine also caused subjects to increase both the peak and static grip forces for all the textures including the 3-mm beaded surface, suggesting that for two of the three surfaces they were responding to the increased slipperiness of the skin due to reduced sweat production.
    Materialart: Digitale Medien
    URL: http://dx.doi.org/10.1007/PL00005666
    Bibliothek Standort Signatur Band/Heft/Jahr Verfügbarkeit
    BibTip Andere fanden auch interessant ...
    Artikel (Nationallizenzen)
    Volltext
  • 2
    Digitale Medien
    Digitale Medien
    Comparison of the effects of Alzheimer's disease, normal aging and scopolamine on human transient visual evoked potentials (1990)
    Springer
    Psychopharmacology 102 (1990), S. 535-543 
    Details
    ISSN: 1432-2072
    Schlagwort(e): Alzheimer's disease ; Aging ; Scopolamine ; Transient visual evoked potentials
    Quelle: Springer Online Journal Archives 1860-2000
    Thema: Medizin
    Notizen: Abstract Transient visual evoked potentials elicited by the onset of a patterned stimulus were recorded in patients suffering from Alzheimer's disease (AD), in healthy elderly controls and in healthy young individual. The latencies and amplitudes of both the components studied were adversely affected by normal aging and one of the components, CI, but not the other, CII, showed further deterioration in AD. These changes occurred over a range of stimulus contrast levels. The changes found in AD, but not those seen in normal aging, could be mimicked by administration of the cholinergic antagonist scopolamine to young volunteers.
    Materialart: Digitale Medien
    URL: http://dx.doi.org/10.1007/BF02247137
    Bibliothek Standort Signatur Band/Heft/Jahr Verfügbarkeit
    BibTip Andere fanden auch interessant ...
    Artikel (Nationallizenzen)
    Volltext
  • 3
    Digitale Medien
    Digitale Medien
    Preclinical evaluation of copper-67 labelled anti-MUC1 mutin antibody C595 for therapeutic use in bladder cancer (1997)
    Springer
    European journal of nuclear medicine 24 (1997), S. 439-443 
    Details
    ISSN: 1619-7089
    Schlagwort(e): Radioimmunotherapy ; MUC1 mucin ; Monoclonal antibody ; Copper-67 ; Bladder cancer
    Quelle: Springer Online Journal Archives 1860-2000
    Thema: Medizin
    Notizen: Abstract Transitional cell carcinoma of the bladder is the fifth commonest cause of death from cancer in men in the United Kingdom. Most patients present early with superficial disease, though with current treatment up to 20% progress to invasive disease, which has a poor prognosis. Better local treatments are required to limit this tumour progression. The ease of access to the bladder via a catheter provides the ideal opportunity for antibody (Ab) targeted therapy. We have previously shown that indium-111 labelled anti-MUCI mucin Ab C595 selectively localises to bladder tumours after intravesical administration. We have selected copper-67 as an alternative radiolabel with suitable physical characteristics for radioimmunotherapy. This communication demonstrates that C595 can be reproducibly labelled with67Cu and that the radioimmunoconjugate is both stable and maintains high immunoreactivity. Pilot studies on cystectomy specimens in a novel ex vivo system and in one patient confirmed the ability of this conjugate to localise to tumour after intravesical administration. On the basis of these studies we are now in a position to study the intravesical administration of67Cu-labelled C595 in patients with bladder cancer with a view to a therapeutic trial.
    Materialart: Digitale Medien
    URL: http://dx.doi.org/10.1007/BF00881818
    Bibliothek Standort Signatur Band/Heft/Jahr Verfügbarkeit
    BibTip Andere fanden auch interessant ...
    Artikel (Nationallizenzen)
    Volltext
  • 4
    Digitale Medien
    Digitale Medien
    Preclinical evaluation of copper-67 labelled anti-MUC1 mucin antibody C595 for therapeutic use in bladder cancer (1997)
    Springer
    European journal of nuclear medicine 24 (1997), S. 439-443 
    Details
    ISSN: 1619-7089
    Schlagwort(e): Key words: Radioimmunotherapy ; MUC1 mucin ; Monoclonal antibody ; Copper-67 ; Bladder cancer
    Quelle: Springer Online Journal Archives 1860-2000
    Thema: Medizin
    Notizen: Abstract. Transitional cell carcinoma of the bladder is the fifth commonest cause of death from cancer in men in the United Kingdom. Most patients present early with superficial disease, though with current treatment up to 20% progress to invasive disease, which has a poor prognosis. Better local treatments are required to limit this tumour progression. The ease of access to the bladder via a catheter provides the ideal opportunity for antibody (Ab) targeted therapy. We have previously shown that indium-111 labelled anti-MUC1 mucin Ab C595 selectively localises to bladder tumours after intravesical administration. We have selected copper-67 as an alternative radiolabel with suitable physical characteristics for radioimmunotherapy. This communication demonstrates that C595 can be reproducibly labelled with 67Cu and that the radioimmunoconjugate is both stable and maintains high immunoreactivity. Pilot studies on cystectomy specimens in a novel ex vivo system and in one patient confirmed the ability of this conjugate to localise to tumour after intravesical administration. On the basis of these studies we are now in a position to study the intravesical administration of 67Cu-labelled C595 in patients with bladder cancer with a view to a therapeutic trial.
    Materialart: Digitale Medien
    URL: http://dx.doi.org/10.1007/BF00881818
    Bibliothek Standort Signatur Band/Heft/Jahr Verfügbarkeit
    BibTip Andere fanden auch interessant ...
    Artikel (Nationallizenzen)
    Volltext
Schließen ⊗
Diese Webseite nutzt Cookies und das Analyse-Tool Matomo. Weitere Informationen finden Sie hier...